Islatravir
Treatment of HIV-1 infection and long-acting pre-exposure prophylaxis (PrEP)
- CAS No.
- 865363-93-5
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Anti-infective / HIV
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A novel nucleoside reverse-transcriptase translocation inhibitor (NRTTI) with long-acting dosing, the core evolution of HIV treatment and prevention, high strategic value.
Anti-infective / HIV · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Islatravir is a pioneering nucleoside reverse transcriptase translocation inhibitor with an ultra long half-life, used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Supply source: Unibest · Islatravir, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.